U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Hanlim Pharm Co., Ltd. - 553021 - 08/25/2022
  1. Warning Letters

CLOSEOUT LETTER

Hanlim Pharm Co., Ltd. MARCS-CMS 553021 —

Product:
Drugs
Recipient:
Recipient Name
Mr. Daniel SC Park
Recipient Title
Plant Manager
Hanlim Pharm Co., Ltd.

2-27, Yeongmun-ro
Cheoin-gu
Yongin-si
Gyeonggi-do
17040
South Korea

Issuing Office:
Center for Drug Evaluation and Research

United States

Dear Mr. Park:

The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter 320-19-01 dated October 3, 2018.

Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability or these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Rokhsana Safaai-Jazi
Compliance Officer
Division of Drug Quality II

Back to Top